HCPCS V2715 is officially defined as "Prism, per lens." HCPCS V2715 is referenced in 2 tracked payer policy changes from Alaska Medicaid and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS V2715 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Alaska Medicaid has clarified vision service authorization requirements and provided specific guidance on how to properly complete authorization requests. The policy specifies which vision products require prior authorization and requires providers to indicate the reason for authorization in box 16 of the form.
Aetna's Clinical Policy Bulletin 0419 covers treatments for Graves' ophthalmopathy (thyroid eye disease) under commercial medical plans. Aetna considers teprotumumab-trbw (Tepezza) medically necessary for adults 18 or older with moderate-to-severe active or inactive disease, for one course of 8 infusions, and considers repeat courses and all other indications experimental, investigational, or unproven. Orbital decompression, eye muscle surgery, eyelid surgery and orbital radiotherapy are medically necessary for severe disease only when conservative measures and medications have not been successful.
Watch V2715
Get one email when a payer policy names V2715, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for V2715
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for V2715 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.